eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
3/2024
vol. 26
 
Share:
Send email
Share:
Review paper

Is metformin a new weapon against cancer? – a literature review

Małgorzata Koziarska-Rościszewska
1
,
Sara Tomaszek
2
,
Katarzyna Mińkowska
2

  1. Nephrology, Hypertension and Family Medicine Department, Medical University of Lodz, Lodz, Poland
  2. Students’ Scientific Association of Family Medicine, Medical University of Lodz, Lodz, Poland
Family Medicine & Primary Care Review 2024; 26(3): 383–388
DOI: https://doi.org/10.5114/fmpcr.2024.142013
Online publish date: 2024/09/30
Article file
- 14 FM&PCR 3 24 - R - Koziarska-Rościszewska - 1425 - Is metformin.pdf  [0.59 MB]
Get citation
 
PlumX metrics:
 
1. Mutschler E, Geisslinger G, Kroemer HK, et al. Farmakologia i toksykologia. Podręcznik. Wrocław: MedPharm Polska; 2015 (in Polish).
2. Naseri A, Sanaie S, Hamzehzadeh S, et al. Metformin: new applications for an old drug. J Basic Clin Physiol Pharmacol 2022; 34(2): 151–160, doi: 10.1515/jbcpp-2022-0252.
3. Shenfield G. Metformin: myths, misunderstandings and lessons from history. Aust Prescr 2013; 36: 38–39, doi: 10.18773/austprescr.2013.017.
4. LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. Endocr Rev 2021; 42(1): 77–96, doi: 10.1210/endrev/bnaa023.
5. Szczeklik A. Interna Szczeklika. Mały podręcznik. Kraków: Medycyna Praktyczna; 2022 (in Polish).
6. Triggle CR, Mohammed I, Bshesh K, et al. Metformin: Is it a drug for all reasons and diseases? Metabolism 2022; 133: 155223, doi: 10.1016/j.metabol.2022.155223.
7. Zhou J, Massey S, Story D, et al. Metformin: An Old Drug with New Applications. Int J Mol Sci 2018; 19(10): 2863, doi: 10.3390/ijms19102863.
8. Liu J, Zhang M, Deng D, et al. The function, mechanisms, and clinical applications of metformin: potential drug, unlimited potentials. Arch Pharm Res 2023; 46(5): 389–407, doi: 10.1007/s12272-023-01445-2.
9. Metformin-associated lactic acidosis and factors associated with 30-day mortality [cited 02.09.2024]. Available from URL: https://pubmed.ncbi.nlm.nih.gov/36040976/.
10. Blough B, Moreland A, Mora A, Jr. Metformin-induced lactic acidosis with emphasis on the anion gap. Proc (Bayl Univ Med Cent) 2015; 28(1): 31–33, doi: 10.1080/08998280.2015.11929178.
11. Di Mauro S, Filippello A, Scamporrino A, et al. Metformin: When Should We Fear Lactic Acidosis? Int J Mol Sci 2022; 23(15): 8320, doi: 10.3390/ijms23158320.
12. World Cancer Research Fund International: “Worldwide cancer data” [cited 01.08.2023]. Available from URL: https://www.wcrf.org/cancer-trends/worldwide-cancer-data/.
13. International Agency for Research on Cancer: “Cancer today” [cited 01.08.2023]. Available from URL: https://gco.iarc.fr/today/data/factsheets/populations/616-poland-fact-sheets.pdf.
14. Kordek R, Jassem J. Onkologia. Podręcznik dla studentów i lekarzy. Gdańsk: Via Medica; 2019 (in Polish).
15. Roett MA, Evans P. Ovarian cancer: an overview. Am Fam Physician 2009; 80(6): 609–616.
16. Penny SM. Ovarian Cancer: An Overview. Radiol Technol 2020; 91(6): 561–575.
17. Wen KC, Sung PL, Wu ATH, et al. Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer. J Ovarian Res 2020; 13(1): 95, doi: 10.1186/s13048-020-00703-x.
18. Shank JJ, Yang K, Ghannam J, et al. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol 2012; 127(2): 390–397, doi: 10.1016/j.ygyno.2012.07.115.
19. Yang C, Zhao N, Li D, et al. Metformin improves the sensitivity of ovarian cancer cells to chemotherapeutic agents. Oncol Lett 2019; 18(3): 2404–2411, doi: 10.3892/ol.2019.10564.
20. Makker V, MacKay H, Ray-Coquard I, et al. Endometrial cancer. Nat Rev Dis Primers 2021; 7(1): 88, doi: 10.1038/s41572-021-00324-8.
21. Passarello K, Kurian S, Villanueva V. Endometrial Cancer: An Overview of Pathophysiology, Management, and Care. Semin Oncol Nurs 2019; 35(2): 157–165, doi: 10.1016/j.soncn.2019.02.002.
22. Ghalib Farhood R, Abd Ali Al-Humairi I. Immunohistochemical Study of Ki-67 in Hyperplastic and Endometrium Carcinoma: A Comparative Study. Arch Razi Inst 2022; 77(1): 229–234, doi: 10.22092/ARI.2021.356540.1865.
23. Petchsila K, Prueksaritanond N, Insin P, et al. Effect of Metformin For Decreasing Proliferative Marker in Women with Endometrial Cancer: A Randomized Double-blind Placebo-Controlled Trial. Asian Pac J Cancer Prev 2020; 21(3): 733–741, doi: 10.31557/APJCP.2020.21.3.733.
24. Mitsuhashi A, Kawasaki Y, Hori M, et al. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial). BMJ Open 2020; 10(2): e035416, doi: 10.1136/bmjopen-2019-035416.
25. Ravi RD, Kalra J, Srinivasan R, et al. A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women. Asian Pac J Cancer Prev 2021; 22(3): 983–989, doi: 10.31557/APJCP.2021.22.3.983.
26. World Health Organization: “Cancer” [cited 01.08.2023]. Available from URL: https://www.who.int/news-room/fact-sheets/detail/cancer.
27. Wörmann B. Breast cancer: basics, screening, diagnostics and treatment. Med Monatsschr Pharm 2017; 40(2): 55–64.
28. Kell MR. Breast cancer: from Halsted to Harney. Ir J Med Sci 2015; 184(1): 77–80, doi: 10.1007/s11845-014-1142-z.
29. Lawrence WR, Hosler AS, Gates Kuliszewski M, et al. Impact of preexisting type 2 diabetes mellitus and antidiabetic drugs on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer. Cancer Epidemiol 2020; 66: 101710, doi: 10.1016/j.canep.2020.101710.
30. Serageldin MA, Kassem AB, El-Kerm Y, et al. The Effect of Metformin on Chemotherapy-Induced Toxicities in Non-diabetic Breast Cancer Patients: A Randomised Controlled Study. Drug Saf 2023; 46(6): 587–599, doi: 10.1007/s40264-023-01305-4.
31. Nayfield SG. Tamoxifen’s role in chemoprevention of breast cancer: an update. J Cell Biochem Suppl 1995; 22: 42–50, doi: 10.1002/jcb.240590807.
32. Ma J, Guo Y, Chen S, et al. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC Cancer 2014; 14: 172, doi: 10.1186/1471-2407-14-172.
33. Alipour S, Abedi M, Saberi A, et al. Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial. BMC Endocr Disord 2021; 21(1): 169, doi: 10.1186/s12902-021-00824-4.
34. Schatten H. Brief Overview of Prostate Cancer Statistics, Grading, Diagnosis and Treatment Strategies. Adv Exp Med Biol 2018; 1095: 1–14, doi: 10.1007/978-3-319-95693-0_1.
35. Wasim S, Lee SY, Kim J. Complexities of Prostate Cancer. Int J Mol Sci 2022; 23(22): 14257, doi: 10.3390/ijms232214257.
36. Nguyen MM, Martinez JA, Hsu CH, et al. Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort. Eur J Cancer Prev 2018; 27(6): 557–562, doi: 10.1097/CEJ.0000000000000394.
37. Wilson BE, Armstrong AJ, de Bono J, et al. Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. Eur J Cancer 2022; 170: 296–304, doi: 10.1016/j.ejca.2022.03.042.
38. Kim JO, McDonald MO, Ong A, et al. Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial. Radiat Oncol 2021; 16(1): 212, doi: 10.1186/s13014-021-01935-x.
39. Rozanec JJ, Secin FP. Epidemiología, etiología, prevención del cáncer vesical [Epidemiology, etiology and prevention of bladder cancer]. Arch Esp Urol 2020; 73(10): 872–878 (in Spanish).
40. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66(6 Suppl. 1): 4–34, doi: 10.1016/j.urology.2005.07.062.
41. Wang Z, Ong WYF, Shen T, et al. Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer. Singapore Med J 2022; 63(4): 209–213, doi: 10.11622/smedj.2020121.
42. Chi BJ, Sun Y, Quan LL, et al. Metformin Can Enhance the Inhibitory Effect of Olaparib in Bladder Cancer Cells. Dis Markers 2022; 2022: 5709259, doi: 10.1155/2022/5709259.
43. Seale DD, Beaver BM. Pathophysiology of lung cancer. Nurs Clin North Am 1992; 27(3): 603–613.
44. Rodriguez-Canales J, Parra-Cuentas E, Wistuba II. Diagnosis and Molecular Classification of Lung Cancer. Cancer Treat Res 2016; 170: 25–46, doi: 10.1007/978-3-319-40389-2_2.
45. Wang Z, Lu C, Zhang K, et al. Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination. Front Mol Biosci 2022; 9: 780200, doi: 10.3389/fmolb.2022.780200.
46. Brancher S, Støer NC, Weiderpass E, et al. Metformin use and lung cancer survival: a population-based study in Norway. Br J Cancer 2021; 124(5): 1018–1025, doi: 10.1038/s41416-020-01186-9.
47. Wang H, Yang X, Sun Y, et al. Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer. Transl Cancer Res 2020; 9(1): 372–381, doi: 10.21037/tcr.2019.11.09.
48. Andrei P, Battuello P, Grasso G, et al. Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. Semin Cancer Biol 2022; 84: 199–213, doi: 10.1016/j.semcancer.2021.04.007.
49. Jordan P. Colorectal Cancer Subtypes – The Current Portrait. Adv Exp Med Biol 2018; 1110: 1–6, doi: 10.1007/978-3-030-02771-1_1.
50. Bragagnoli AC, Araujo RLC, Ferraz MW, et al. Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial. Br J Cancer 2021; 124(6): 1072–1078, doi: 10.1038/s41416-020-01208-6.
51. Higurashi T, Hosono K, Takahashi H, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol 2016; 17(4): 475–483, doi: 10.1016/S1470-2045(15)00565-3.
52. Lee JH, Kim TI, Jeon SM, et al. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 2012; 131(3): 752–759, doi: 10.1002/ijc.26421.
Copyright: © 2024 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.